Your NEJM Group Today: Cancer Drug Development, Hemophilia, New Jersey IM Opportunity (FREE)
By the Editors NEJM Group offers so many valuable resources for practicing clinicians. Here's what we chose for you today:NEJM Audio Interview: Rethinking Oncology Trials: Dr. Alice Shaw discusses … (Source: Physician's First Watch current issue)
Source: Physician's First Watch current issue - May 26, 2016 Category: Primary Care Source Type: news

In hemophilia A, emicizumab cuts bleeding; plasma-derived factor VIII less likely to trigger antibodies
Patients with severe hemophilia A treated with plasma-derived factor VIII, as compared with recombinant factor VIII, had a lower risk of developing neutralizing antibodies, based on a recent report... (Source: Pediatric News)
Source: Pediatric News - May 25, 2016 Category: Journals (General) Source Type: news

2 New Findings Offer Hope for Those With Severe Hemophilia
WEDNESDAY, May 25, 2016 -- Two new studies could pave the way to major changes in how doctors treat severe cases of hemophilia -- a rare genetic disorder that can cause uncontrolled bleeding. Both studies tackle a key challenge: Up to one-third of... (Source: Drugs.com - Daily MedNews)
Source: Drugs.com - Daily MedNews - May 25, 2016 Category: Journals (General) Source Type: news

Stebbins, Cocohoba leading specialty drug study with Walgreens
So-called specialty drugs can represent lifesaving advances in the treatment of serious complex conditions, such as cancers, hepatitis C, rheumatoid arthritis, multiple sclerosis, and inflammatory bowel disease. They can turn once routinely lethal diseases such as HIV and cystic fibrosis into manageable chronic conditions. They can address rare genetic conditions, such as hemophilia, or suppress immune rejection after organ transplants. (Source: UCSF School of Pharmacy News)
Source: UCSF School of Pharmacy News - May 24, 2016 Category: Universities & Medical Training Authors: Paula Joyce Source Type: news

Facial and Scalp Swelling in Children With HemophiliaFacial and Scalp Swelling in Children With Hemophilia
Two pediatric patients present with swelling of the cheek and scalp. Find out how these cases were diagnosed and learn what the treatment was. ePlasty, Open Access Journal of Plastic Surgery (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - May 24, 2016 Category: Consumer Health News Tags: Plastic Surgery & Aesthetic Medicine Journal Article Source Type: news

Hemophilia Products Do Not Raise Antibody Risk, Says EMAHemophilia Products Do Not Raise Antibody Risk, Says EMA
The evidence does not indicate that two recombinant factor VIII products from Bayer increase the risk for inhibitors that render treatment ineffective, EU regulators said in a meta-analysis. News Alerts (Source: Medscape Internal Medicine Headlines)
Source: Medscape Internal Medicine Headlines - May 13, 2016 Category: Internal Medicine Tags: Hematology-Oncology News Alert Source Type: news

Alprolix(R) (rFIXFc) approved in the EU for the treatment of haemophilia B
First Fc Fusion therapy approved for haemophilia B in the EU to provide extended protection against bleeds STOCKHOLM--(Healthcare Sales & Marketing Network)--Swedish Orphan Biovitrum AB (publ) (http://www.sobi.com/) (Sobi™) (SOBI.ST) and Biogen (http://... Biopharmaceuticals, RegulatorySwedish Orphan Biovitrum, Sobi, Biogen, Alprolix, haemophilia B, hemophilia B (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - May 13, 2016 Category: Pharmaceuticals Source Type: news

Biogen to Spin Off Multi-Million-Dollar Hemophilia Biz
The new company will focus on the discovery and development of hemophilia therapies, with existing marketed products to include ELOCTATE and ALPROLIX, which had combined revenues of $640M during the last 12-month period (Source: PharmaManufacturing.com)
Source: PharmaManufacturing.com - May 4, 2016 Category: Pharmaceuticals Source Type: news

Biogen to Spin Off Hemophilia Unit
Biogen Inc. said it plans to spin off its hemophilia business as a publicly traded company so the biotechnology company can increase its focus on neurology drugs. (Source: WSJ.com: Health)
Source: WSJ.com: Health - May 4, 2016 Category: Pharmaceuticals Tags: FREE Source Type: news

Biogen to spin off hemophilia drugs and focus on core neuro business
(Reuters) - Biogen Inc plans to spin off its hemophilia drug business as a publicly traded company, leaving the drugmaker to focus on developing drugs for neurodegenerative diseases, the company said on Tuesday. (Source: Reuters: Health)
Source: Reuters: Health - May 3, 2016 Category: Consumer Health News Tags: healthNews Source Type: news

Making Pharma Personal
Paul Perreault, CEO and Managing Director of biotherapies company CSL Behring, often receives messages from people celebrating the great landmarks in their lives. There is nothing so very extraordinary about that – except these are from patients whom he has helped during his time in the business. “I wasn’t always an executive, so I started in the business, and I know patients and their families personally, across the country,” he begins. “At different levels of jobs that I’ve had in the organization, I’ve interacted with patients on a very direct and one-on-one level. And I was aro...
Source: EyeForPharma - April 28, 2016 Category: Pharmaceuticals Authors: Adam Hill Source Type: news

Novo Nordisk, Baxalta entering India market, to benefit Hemophilia A patients
While Novo Nordisk's 'NovoEight' was launched this week at half its international price, Baxalta will bring 'ADVATE' to the country in the second-half of 2016. (Source: The Economic Times Healthcare and Biotech News)
Source: The Economic Times Healthcare and Biotech News - April 28, 2016 Category: Pharmaceuticals Source Type: news

Enthusiasm for Prehospital Use of TXA May Be Premature
Tranexamic acid (TXA), an antifibrinolytic drug, has been used by clinicians since 1986 when it was first approved by the Food and Drug Administration for the reduction and prevention of hemorrhage in patients with hemophilia undergoing tooth extraction. Since then, it's been used as an "off-label" medication in cardiac and orthopedic surgery as a means to reduce intraoperative blood loss. Recently this off-label use has expanded to trauma patients based on enthusiasm from two studies known as CRASH-2 and MATTERS (discussed later). Today TXA is used in some hospitals in the United States, and there's been in...
Source: JEMS Patient Care - April 27, 2016 Category: Emergency Medicine Authors: Adam Fox, DPM, DO Tags: Trauma Source Type: news

Factor IX Agent Effective in Hemophilia B (CME/CE)
(MedPage Today) -- Spontaneous, joint bleeds prevented by albumin-bound product (Source: MedPage Today Hematology/Oncology)
Source: MedPage Today Hematology/Oncology - April 17, 2016 Category: Hematology Source Type: news

Asset Sale Rumors: What Do They Mean for Biogen?
On Friday, Reuters reported -- according to sources -- that Biogen is potentially exploring a sale of its hemophilia treatments to increase focus on core therapeutic areas. (Source: PharmaManufacturing.com)
Source: PharmaManufacturing.com - April 12, 2016 Category: Pharmaceuticals Source Type: news

A severely burned hemophiliac - Boliglowa DK, Pierson T, Ryu SM, Menke H.
Patients suffering from moderate or severe hemophilia A are particularly vulnerable to trauma injury, being on high risk of immediate exsanguination. Due to a rareness of this disease, there are very few reports about the management of severe injuries of t... (Source: SafetyLit)
Source: SafetyLit - April 11, 2016 Category: Global & Universal Tags: Burns, Electricity, Explosions, Fire, Scalds Source Type: news

Biogen explores sale of hemophilia assets: sources
(Reuters) - Biogen Inc, one of the world's largest biotechnology companies, is exploring a sale of its hemophilia treatments, as it increases its focus on core therapeutic areas, according to people familiar with the matter. (Source: Reuters: Health)
Source: Reuters: Health - April 8, 2016 Category: Consumer Health News Tags: healthNews Source Type: news

Bayer Receives Approval for Kovaltry® for the Treatment of Hemophilia A in Japan (for specialized target groups only)
(Source: Bayer Company News)
Source: Bayer Company News - March 29, 2016 Category: Pharmaceuticals Source Type: news

UC San Diego Health joins National Clinical Trial on hemophilia B gene therapy
(University of California - San Diego) The Hemophilia and Thrombosis Treatment Center at UC San Diego Health has joined a nationwide clinical trial testing a potential gene therapy that may one day provide a better and long-lasting treatment for people with hemophilia B. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - March 22, 2016 Category: Global & Universal Source Type: news

Bayer's Kovaltry receives FDA approval to treat haemophilia A
German pharmaceutical company Bayer has received approval from the US Food and Drug Administration (FDA) for Kovaltry Antihemophilic Factor (Recombinant) for the treatment of children and adults with haemophilia A. (Source: Pharmaceutical Technology)
Source: Pharmaceutical Technology - March 18, 2016 Category: Pharmaceuticals Source Type: news

FDA Approves Bayer's Kovaltry (Antihemophilic Factor (Recombinant)) for the Treatment of Children and Adults with Hemophilia A
WHIPPANY, N.J., March 17, 2016 /PRNewswire/ -- The U.S. Food and Drug Administration has approved Bayer's Kovaltry Antihemophilic Factor (Recombinant), an unmodified, full-length factor VIII compound for the treatment of hemophilia A in children and... (Source: Drugs.com - New Drug Approvals)
Source: Drugs.com - New Drug Approvals - March 18, 2016 Category: Drugs & Pharmacology Source Type: news

FDA Clears Factor VIII Product Kovaltry for Hemophilia AFDA Clears Factor VIII Product Kovaltry for Hemophilia A
Studies show routine prophylaxis with Kovaltry helps controls bleeds and reduces frequency of bleeding episodes in children and adults with hemophilia A. FDA Approvals (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - March 17, 2016 Category: Cancer & Oncology Tags: Hematology-Oncology News Source Type: news

FDA approves two new hemophilia therapies
The Food and Drug Administration has approved Idelvion, the first hemophilia B therapy with up to 14-day dosing intervals, and Kovaltry, an unmodified, full-length factor VIII compound for the... (Source: Pediatric News)
Source: Pediatric News - March 17, 2016 Category: Journals (General) Source Type: news

Germany's Bayer secures U.S. FDA approval for hemophilia A therapy
(Reuters) - The U.S. Food and Drug Administration approved Bayer AG's therapy for the most common form hemophilia, the company said on Thursday, about three weeks after the treatment was cleared for use in Europe. (Source: Reuters: Health)
Source: Reuters: Health - March 17, 2016 Category: Consumer Health News Tags: healthNews Source Type: news

With FDA approval, Berkeley's got a brand new drug
A next-generation blood-clotting treatment — made and tested at Bayer HealthCare's Berkeley campus — won approval from the Food and Drug Administration for use by hemophilia A patients, the company said Thursday. FDA approval of Kovaltry, which last month scored European and Canadian regulatory approvals, is a next-step move by Bayer to protect and build on its longtime hemophilia A franchise. Kogenate FS for hemophilia A patients is the German company's second-best-selling product, and Bayer… (Source: bizjournals.com Health Care:Pharmaceuticals headlines)
Source: bizjournals.com Health Care:Pharmaceuticals headlines - March 17, 2016 Category: Pharmaceuticals Authors: Ron Leuty Source Type: news

Bayer Receives FDA Approval for Kovaltry® for the Treatment of Children and Adults with Hemophilia A (for specialized target groups only)
(Source: Bayer Company News)
Source: Bayer Company News - March 17, 2016 Category: Pharmaceuticals Source Type: news

Review Finds Mixed Success With Hemophilia Treatment
Researchers surprised by shortcomings in treatment of men with severe forms of the blood-clotting disorder (Source: U.S. News - Health)
Source: U.S. News - Health - March 16, 2016 Category: Consumer Health News Source Type: news

Review Finds Mixed Success with Hemophilia Treatment
Researchers surprised by shortcomings in treatment of men with severe forms of the blood-clotting disorder Source: HealthDay Related MedlinePlus Page: Hemophilia (Source: MedlinePlus Health News)
Source: MedlinePlus Health News - March 16, 2016 Category: Consumer Health News Source Type: news

Review Finds Mixed Success With Hemophilia Treatment
WEDNESDAY, March 16, 2016 -- Though the past 50 years have brought major treatment advances, men with severe hemophilia are still at high risk for bleeding and physical disability, experts say. Hemophilia is a genetic disease that prevents blood... (Source: Drugs.com - Daily MedNews)
Source: Drugs.com - Daily MedNews - March 16, 2016 Category: Journals (General) Source Type: news

Partner your Way to Patient-Centric Impact
In 2001, leadership at Novo Nordisk, the global leader in diabetes care, noticed something troubling; a large proportion of people with diabetes were not in control of their condition. Within diabetes care, control is tracked by the A1C test, which measures the percentage of glycated hemoglobin as an indicator for high blood glucose. Patients on therapy are considered in good glycemic control if their percentage of glycated hemoglobin reads at less than 7%; shockingly, over 50% of patients were failing this threshold. With highly effective medical therapies being available, the data suggested people with diabetes weren&rsq...
Source: EyeForPharma - March 14, 2016 Category: Pharmaceuticals Authors: Thomas Disley Source Type: news

Idelvion approved for hemophilia B
HealthDay News Idelvion has been approved by the U.S. Food and Drug Administration to replace a deficient blood clotting factor among people with hemophilia B. (Source: Health News - UPI.com)
Source: Health News - UPI.com - March 7, 2016 Category: Consumer Health News Source Type: news

Idelvion Approved for Hemophilia B
Replaces deficient clotting factor (Source: U.S. News - Health)
Source: U.S. News - Health - March 7, 2016 Category: Consumer Health News Source Type: news

Idelvion Approved for Hemophilia B
MONDAY, March 7, 2016 -- Idelvion has been approved by the U.S. Food and Drug Administration to replace a deficient blood clotting factor among people with hemophilia B. The product -- which has the generic name of "coagulation Factor IX, albumin... (Source: Drugs.com - Daily MedNews)
Source: Drugs.com - Daily MedNews - March 7, 2016 Category: Journals (General) Source Type: news

Baxalta doses first patient in Phase I trial of BAX 826 to treat haemophilia A
US-based biopharmaceutical firm Baxalta has begun its Phase I clinical trial evaluating BAX 826, a recombinant Factor VIII (rFVIII) treatment for haemophilia A. (Source: Drug Development Technology)
Source: Drug Development Technology - March 7, 2016 Category: Pharmaceuticals Source Type: news

Hemophilia B Treatment Approved (FREE)
By Kristin J. Kelley Edited by Susan Sadoughi, MD, and André Sofair, MD, MPH The FDA has approved the first coagulation factor-albumin fusion protein (marketed as Idelvion) to … (Source: Physician's First Watch current issue)
Source: Physician's First Watch current issue - March 7, 2016 Category: Primary Care Source Type: news

FDA Approves Idelvion for Hemophilia BFDA Approves Idelvion for Hemophilia B
This combination of factor IX and albumin makes the drug last longer in the bloodstream, potentially requiring fewer injections than unmodified clotting factor. FDA Approvals (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - March 5, 2016 Category: Consumer Health News Tags: Hematology-Oncology News Alert Source Type: news

'Black death' offers clues to battling HIV, hepatitis C centuries later
The Black Death swept Europe in the 14th century eliminating up to half of the population but it left genetic clues that now may aid a researcher in treating HIV patients co-infected with hepatitis C using an anti-retroviral drug therapy. A new study will look at the blood samples of nearly 3,000 patients, primarily individuals with hemophilia, who were exposed to HIV during the early 1980s and late 1990s, to see if an inherited genetic variant that protects against HIV might also help prevent injury from Hepatitis C and other liver diseases. (Source: ScienceDaily Headlines)
Source: ScienceDaily Headlines - March 4, 2016 Category: Science Source Type: news

FDA approves first coagulation factor-albumin fusion protein to treat patients with hemophilia B
The U.S. Food and Drug Administration today approved Idelvion, Coagulation Factor IX (Recombinant), Albumin Fusion Protein, for use in children and adults with Hemophilia B. Idelvion is the first coagulation factor-albumin fusion protein product to be approved, and the second Factor IX fusion protein product approved in the U.S. that is modified to last longer in the blood. (Source: Food and Drug Administration)
Source: Food and Drug Administration - March 4, 2016 Category: American Health Source Type: news

FDA Approves Idelvion (coagulation factor IX (recombinant), albumin fusion protein) to Treat Patients with Hemophilia B
March 4, 2016 -- The U.S. Food and Drug Administration today approved Idelvion, Coagulation Factor IX (Recombinant), Albumin Fusion Protein, for use in children and adults with Hemophilia B. Idelvion is the first coagulation factor-albumin fusion... (Source: Drugs.com - New Drug Approvals)
Source: Drugs.com - New Drug Approvals - March 4, 2016 Category: Drugs & Pharmacology Source Type: news

Dr. Holbrook Kohrt, Hemophiliac Who Made the Condition a Crusade, Dies at 38
Inspired by his own body’s ability to suppress disease, Dr. Kohrt pursued a medical career that coupled basic science with a clinical practice. (Source: NYT Health)
Source: NYT Health - March 1, 2016 Category: Consumer Health News Authors: SAM ROBERTS Tags: Stanford University Deaths (Obituaries) Kohrt, Holbrook E Hemophilia Immune System Source Type: news

OPKO begins dosing in Phase IIa trial of Factor VIIa-CTP to treat hemophilia
US-based OPKO Health has started dosing in a Phase IIa dose escalation trial to evaluate the safety of a long-acting Factor VIIa to treat patients with hemophilia. (Source: Drug Development Technology)
Source: Drug Development Technology - February 24, 2016 Category: Pharmaceuticals Source Type: news

EU approves Bayer's Kovaltry for haemophilia A
FRANKFURT (Reuters) - The European Commission has approved Bayer's haemophilia A drug Kovaltry for the treatment of patients from all age groups, the company said on Monday. (Source: Reuters: Health)
Source: Reuters: Health - February 22, 2016 Category: Consumer Health News Tags: healthNews Source Type: news

Bayer Receives EU Approval of Kovaltry® for Treatment of Hemophilia A (for specialized target groups only)
(Source: Bayer Company News)
Source: Bayer Company News - February 22, 2016 Category: Pharmaceuticals Source Type: news

Hemophilia Patient or Drug Seller? Dual Role Creates Ethical Quandary
When hemophiliacs make their living by selling lucrative hemophilia drugs, patient advocates say it creates a dangerous conflict of interest. (Source: NYT Health)
Source: NYT Health - January 13, 2016 Category: Consumer Health News Authors: ANDREW POLLACK Tags: Ethics and Official Misconduct Drugs (Pharmaceuticals) Novo Nordisk A/S National Hemophilia Foundation Blood MedfusionRx Pfizer Inc Baxalta Bayer AG Hemophilia of North Carolina Conflicts of Interest Source Type: news

Hemophilia: New Treatments for an Old Disease
(Source: eMedicineHealth.com)
Source: eMedicineHealth.com - January 13, 2016 Category: Journals (General) Source Type: news

Hemophilia: New Treatments for an Old Disease
Treating hemophilia can be time-consuming and troublesome. But several newly approved medications, while far from a cure, aim to lift some of that burden. WebMD has the details. (Source: WebMD Health)
Source: WebMD Health - January 12, 2016 Category: Consumer Health News Source Type: news

Sobi(TM) announces commercial launch of Elocta® in first countries in Europe
Swedish Orphan Biovitrum AB announced the commercial launch of Elocta® in first countries in Europe (Source: Pharmacy Europe)
Source: Pharmacy Europe - January 11, 2016 Category: Drugs & Pharmacology Authors: Annabel De Coster Tags: *** Editor's Pick Practical therapeutics Haematology Patient care elocta haemophilia a Latest News recombinant human factor VIII Fc fusion protein Source Type: news

FDA Announces New Blood Donation Policy for MSM
(MedPage Today) -- FDA adopts looser policy for men who have sex with men, continues deferral for hemophiliacs (Source: MedPage Today Ophthalmology)
Source: MedPage Today Ophthalmology - December 21, 2015 Category: Opthalmology Source Type: news